Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Peng, Xing Chen ^a   Yang, Li ^a   Yang, Li Ping ^a   Mao, Yong Qiu ^a   Yang, Han Shuo ^a   Liu, Ji Yan ^a   Zhang, Dong Mei ^a   Chen, Li Juan ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALGINIC ACID; CD31 ANTIGEN; CHOLESTEROL; MUTANT PROTEIN; SODIUM CHLORIDE; SURVIVIN; 1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; ALANINE; LIPOSOME; MICROTUBULE ASSOCIATED PROTEIN; MONOUNSATURATED FATTY ACID; QUATERNARY AMMONIUM DERIVATIVE; SURVIVIN PROTEIN, MOUSE; THREONINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CAPILLARY DENSITY; CELL STRUCTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG METASTASIS; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; NULL ALLELE; PLASMID; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; METASTASIS; PATHOLOGY;

ALANINE; AMINO ACID SUBSTITUTION; ANIMALS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; QUATERNARY AMMONIUM COMPOUNDS; THREONINE;

EID: 54049098299     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-46     Document Type: Article

References (42)

1. Cancer statistics, 2007. A Jemal R Siegel E Ward T Murray J XU MJ Thun, CA Cancer J Clin 2007 57 43 66 17237035
2. Combined therapy of local and metastatic 4T1 breast tumor in mice using SUan inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. X Huang MK Wong H Yi S Watkins AD Laird SF Wolf E Gorelik, Cancer Res 6668 62 5727 5735
3. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B 7.1 cell-based tumor vaccines. BA Pulaski SO Rosenberg, Cancer Res 1998 58 1486 1493 9537252
4. Validating survivin as a cancer therapeutic target. DC Altieri, Nature Cancer Rev 2003 3 46 54 10.1038/nrc968
5. Targeting survivin in cancer therapy: fulfilled promises and open questions. M Pennati M Folini N Zaffaroni, Carcinogenesis 2007 28 6 1133 1139 10.1093/carcin/bgm047 17341657
6. IAP family proteins: suppressors of apoptosis. QL Deveraux JC Reed, Genes Dev 1999 13 239 252 10.1101/gad.13.3.239 9990849
7. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. K Tanaka S Iwamoto G Gon T Nohara M Iwamoto N Tanigawa, Clin Cancer Res 2000 6 127 134 10656440
8. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Zhao T Tenev LM Martins J Downward NR lemoine, J Cell Sci 2000 113 4363 4371 11069780
9. Survivin gene expression and prognosis in recurrent colorectal cancer. M Miller D Smith A Windsor A Kessling, Gut 2001 48 137 138 11200077 10.1136/gut.48.1.137
10. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. J Kato Y Kuwabara M Mitani N Shinoda A Sato T Toyama A Mitsui T Nishiwaki S Moriyama J Kudo Y Fujii, Int J Cancer 2001 95 92 95 10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9 11241318
11. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. AI Sarela CS Verbeke J Ramsdale CL Davies AF Markham PJ Guillou, Br J Cancer 2002 86 886 892 10.1038/sj.bjc.6600133 11953819
12. Survivin as a radioresistance factor in pancreatic cancer. K Asanuma R Moriai T Yajima A Yagihashi M Yamada D Kobayashi N Watanabe, Jpn J Cancer Res 2000 91 1204 1209 11092988
13. Expression of the anti-apoptosis gene survivin correlates with taxol resistance in human ovarian cancer. G Colella N Zaffaroni M Pennati E Benini MG Daidone, Proc Am Assoc Cancer Res 2001 42 302
14. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. X Ling RJ Bernacki MG Brattain F Li, J Biol Chem 2004 279 15 15196 15203 10.1074/jbc.M310947200 14722122
15. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage ii colorectal carcinomas. AI Sarela N Scott J Ramsdale AF Markham PJ Guillou, Ann Surg Oncol 2001 8 4 305 310 10.1007/s10434-001-0305-0 11352303
16. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. JR Kanwar WP Shen RK Kanwar RW Berg GW Krissansen, J Natl Cancer Inst 2001 93 20 1541 1552 11604477
17. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. M Pennati G Colella M Folini L Citti MG Daidone N Zaffaroni, J Clin Invest 2002 109 285 286 11805141
18. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells. F Paduano R Villa M Pennati M Folini M Binda MG Daidone N Zaffaroni, Mol Cancer Ther 2006 5 179 186 10.1158/1535-7163.MCT-05-0132 16432177
19. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. G Jiang J Li Z Zeng L Xian, Cancer Biol Ther 2006 5 435 440 16575205
20. Full-Length Dominant-Negative Survivin for Cancer Immunotherapy. V Pisarev B Yu R Salup S Sherman DI Gabrilovich, Clin Cancer Res 2003 9 6523 6533 14695157
21. Inhibition of melanoma tumor growth in vivo by survivin targeting. D Grossman PJ Kim JS Schechner DC Altieri, Proc Natl Acad Sci USA 2001 98 635 640 11149963 10.1073/pnas.230450097
22. Phase I clinical study of antiapoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. T Tsuruma F Hata T Torigoe T Furuhata S Idenoue T Kurotaki M Yamamoto A Yagihashi T Ohmura K Yamaguchi T Katsuramaki T Yasoshima K Sasaki Y Mizushima H Minamida H Kimura M Akiyama Y Hirohashi H Asanuma Y Tamura K Shimozawa N Sato K Hirata, J Transl Med 2004 2 19 15193151 10.1186/1479-5876-2-19
23. Improved DNA:liposome complexes for increased systemic delivery and gene expression. NS Templeton DD Lasic PM Frederik HH Strey DD Roberts GN Pavlakis, Nature Biotech 1997 15 647 652 10.1038/nbt0797-647
24. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Weidner JP Semple WR Welch J Folkman, N Engl J Med 1991 324 1 8 1701519
25. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. JY Liu YQ Wei L Yang X Zhao L Tian JM Hou T Niu F Liu Y Jiang B Hu Y Wu JM Su YY Lou QM He YJ Wen JL Yang B Kan YQ Mao F Luo F Peng, Blood 2003 102 1815 1823 10.1182/blood-2002-12-3772 12750177
26. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. T Yi YQ Wei L Tian X Zhao J Li HX Deng YJ Wen CH Zou GH Tan B Kan JM Su Y Jiang YQ Mao P Chen YS Wang, Cancer Gene Ther 2007 14 158 164 10.1038/sj.cgt.7700994 17124509
27. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. T Hiraga A Ueda D Tamura K Hata F Ikeda PJ Williams T Yoneda, Int J Cancer 2003 106 973 979 10.1002/ijc.11330 12918079
28. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. T Michigami T Hiraga PJ Williams M Niewolna R Nishimura GR Mundy T Yoneda, Breast Cancer Res 2002 75 249 258 10.1023/A:1019905111666
29. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. T Yoneda T Michigami B Yi PJ Williams M Niewolna T Hiraga, Cancer 2000 88 2979 2988 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0. CO;2-U 10898341
30. Ostrand-Rosenberg S. Cooperativity of staphylococcal aureus entertoxin B superantigen, Major Histocompatibility Complex Class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. BA Pulaski DS Terman S Khan E Muller, Cancer Res 2000 60 2710 2715 10825145
31. Increased uptake of liposome-DNA complexes by lung metastases following intravenous administration. I Ito G Began I Mohiuddin T Saeki Y Saito CD Branch A Vaporciyan LC Stephens N Yen JA Roth R Ramesh, Molecular Ther 2003 7 409 418 10.1016/S1525-0016(03)00004-2
32. Cationic liposome target angiogenic endothelial cells in tumors and chronic inflammation in mice. G Thurston JW Mclean M Rizen P Baluk A Haskell TJ Murphy D Hanahan DM McDonald, J Clin Invest 1998 101 1401 1413 9525983 10.1172/JCI965
33. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung specific stealth liposomes against mycobacterium tuberculosis infection induced in mice. P Deol GK Khuller K Joshi, Antimicrob Agents Chemother 1997 41 1211 9174172
34. The controlled delivery of drugs to the lung. XM Zeng GP Martin C Marriott, International Journal Pharmaceutical 1995 124 149 164 10.1016/0378-5173(95)00104-Q
35. Tumor angiogenesis: therapeutic implications. J Folkman, N Engl J Med 1971 285 1182 1186 4938153
36. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. D Hanahan J Folkman, Cell 1996 86 353 364 10.1016/S0092-8674(00) 80108-7 8756718
37. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. T Browder CE Butterfield BM Kraling B Shi B Marshall MS O'Reilly J Folkman, Cancer Res 2000 60 1878 1886 10766175
38. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. J Dixelius H Larsson T Sasaki K Holmqvist L Lu A Engstrom R Timpl M Welsh L Claesson-Welsh, Blood 2000 95 3403 3411 10828022
39. In situ observation of inflammatory cell-tumor cell interaction in human seminoma (germinoma). YQ Wei ZB Hang KF Liu, Hum Pathol 1998 23 421 429 10.1016/0046-8177(92)90090-P
40. Direct ultrastructural evidence of lymphocyte-mediated cancer cell lysis in the microenvironments of Chinese nasopharygeal carcinomas. ZB Hang YQ Wei YP Wang NR Xu, Hum Pathol 1991 22 320 325 10.1016/0046-8177(91)90079-5 2050365
41. Tumor antigens recognized by T cells. T Boon PG Coulie B Van den Eynde, Immunol Today 1997 18 267 268 10.1016/S0167-5699(97)80020-5 9190110
42. Progress in human tumor immunology and immunotherapy. SA Rosenberg, Nature 2001 411 380 384 10.1038/35077246 11357146